Latest endometrial cancer News

Cancer often requires more than one treatment − an oncologist explains why some patients like Kate Middleton receive both chemotherapy and surgery
Kinder Test Could Improve Diagnosis Of Womb Cancer
New treatment for deadly uterine cancer
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
Mater biobank donors lead fight against ovarian cancer
Common hormone could hold key to treating endometrial cancer
Trial to fill 30-year knowledge gap in cancer surgery
UQ clinical trials and cohort studies receive boost from NHMRC
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial
New treatments for Australians with endometrial cancer and Lennox-Gastaut syndrome
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
We need to talk about ovarian cancer, our deadliest gynaecological cancer
Funding boost for research into deadly cancers affecting women
Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial
TGA Product Information safety updates 2 March
Jeannie Ferris Cancer Australia Recognition Award 10th anniversary recipients revealed
Early-career researchers boosted in mission to beat cancer
Novel blood test could quash endometrial cancer
Having more babies lowers risk of endometrial cancer
Imjudo in combination with Imfinzi approved in US for patients with unresectable liver cancer
Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial
CPTAC renews funding for proteogenomics research at Baylor
Imfinzi plus chemotherapy granted Priority Review in US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase
Tremelimumab accepted under Priority Review in US for patients with unresectable liver cancer
Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive
Prime time: First therapeutic clinical trial of C’Dots underway
Study offers hope of new treatments for endometrial cancer
QIMR Berghofer scientist elected Fellow of Australian Academy of Health and Medical Sciences
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial
5 things to know about bowel cancer
Four foods you should eat & three you should avoid to prevent cancer
Key gene identified in endometrial cancer could be targeted in future drug trial
$26m funding injection for cardiovascular and cancer research
$13.6 million for reproductive, childhood brain and other cancer clinical trials
Dark shadow of type 2 diabetes
Diabetes dramatically increases dementia risk, doubles chance of some cancers
Researchers discover new method of detecting endometrial cancer
Breastfeeding linked to lower ovarian cancer risk
QIMR Berghofer scientist named Cure Cancer Researcher of year
Study identifies risk factors for endometrial cancer
Molecular roadmap boosts fight against endometrial cancer
New research to investigate link between obesity and endometrial cancer
Provisional application receives approval through first international collaborative review initiative between TGA, FDA and HC
Provisional approval of lenvatinib in combination with pembrolizumab for treatment of advanced endometrial carcinoma